Webinar, FAQ Report & Decision Aid | COVID-19 & Neuromuscular Disorders: Ask The Experts
Muscular Dystrophy Canada (MDC) and the Neuromuscular Disease Network for Canada (NMD4C) have received numerous questions about COVID-19 vaccines and how they may uniquely affect people with neuromuscular disorders (NMD).
To address these questions and concerns, MDC & NMD4C assembled a diverse group of neuromuscular, virology, and policy experts to host a webinar with the purpose of answering these topical questions.
From this expert-led webinar, the MDC & NMD4C have developed a frequently asked questions report and decision aid tool as resources to summarize the experts’ answers, and to provide guidance for informed patient decision making.
You can access the Frequently Asked Questions Report, Decision Aid, and webinar recording below!
Report: Frequently Asked Questions – COVID-19 & Neuromuscular Disorders
Decision Aid: I have a NMD, should I get a vaccine for COVID-19
We are excited to have the following experts address questions about NMDs, COVID-19 and vaccines:
- Dr. Hans Katzberg, adult neuromuscular specialist and NMD researcher
- Dr. Hanns Lochmuller, pediatric neuromuscular specialist and NMD researcher
- Dr. Reshma Amin, respirologist and NMD researcher
- Dr. Megan Bettle, Director of the COVID-19 Regulatory Response Team at Health Canada / Government of Canada
- Dr. Allison McGeer, Infectious Disease Specialist and COVID-19 researcher
- Dr. Anne Pham-Huy, Infectious Disease Specialist and Chair of Immunize Canada
Read next...
NMD4C Receive Excellence in Service Delivery Award and Network Investigators Honored as part of Muscular Dystrophy Canada’s 2024 Dr David Green Awards
We are excited to share that the NMD4C has been awarded the Excellence in Service Delivery Award, one of the annual Dr David Green Awards presented by Muscular Dystrophy Canada.
NMD4C Launch Canadian Neuromuscular Clinical Trial Network
We are thrilled to announce the launch of a Canadian neuromuscular clinical trial network (CTN) as a part of our clinical research work.
Training Session for Physiotherapists and Occupational Therapists on Outcome Measures in Spinal muscular atrophy hosted by Quebec SMA Network
This past March 23, the Quebec SMA Network (Réseau québécois de l’amyotrophie spinale – RQAS) in collaboration with the NMD4C and Muscular Dystrophy Canada (MDC) hosted an interactive training session for French-speaking physiotherapists and occupational therapists on assessment measures and practices for Spinal muscular atrophy (SMA). This training gathered clinicians to train and discuss SMA standardized outcome measures and work through current problems/challenges, to improve how these measures often tied to drug reimbursement are conducted.
MDC Announce Recipients of 2024 Neuromuscular Clinical and Translational Research Grants
Muscular Dystrophy Canada (MDC) recently announced the recipients of its annual Neuromuscular Research Grants competition. Through these grants, MDC is investing $900,000 into clinical and translational research projects.
SMA Outcome Measures Training for Physiotherapists and Occupational Therapists
To support the development and training on validated NMD outcome measures we are pleased to provide opportunities for physiotherapists and occupational therapists to attend training sessions for outcome measures.
Congratulations to the 2024 NMD4C Early Career Awards Recipients
We are excited to announce the recipients of the 2024 NMD4C Early Career Awards! This is the second year of our annual award program, celebrating excellence and contribution to the neuromuscular field from early career investigators across both clinical and basic science streams.